Evidence for a serotonergic subtype of major depressive disorder: A NeuroPharm-1 study

Kristin Köhler‐Forsberg,Brice Ozenne, Landman Eb,S.V. Larsen, Poulsen As, Dam Vh,Ip C,Anders Jørgensen,Michal Meyer, Eiberg Hr,Claus Svarer, Jørgensen Mb, Frokjaer Vg,Gitte M. Knudsen

medRxiv (Cold Spring Harbor Laboratory)(2021)

引用 0|浏览0
暂无评分
摘要
Abstract Selective serotonin reuptake inhibitors (SSRIs) are the first line pharmacological treatment of Major Depressive Disorder (MDD), but only about half of patients benefit from it. Cerebral serotonin 4 receptor (5-HT 4 R) binding measured with positron emission tomography (PET) is inversely related to serotonin levels and can serve as a proxy for brain serotonin levels. We here determine if 5-HT 4 R differs between healthy and MDD individuals and if it is associated with successful outcomes of serotonergic treatment of MDD. We [ 11 C]-SB207145 PET-scanned 100 (71 F) untreated patients with moderate to severe MDD and 91 (55 F) healthy controls; 40 patients were re-scanned after 8 weeks treatment. All patients started treatment with the SSRI escitalopram and were followed clinically after 1, 2, 4, 8 and 12 weeks. Treatment response was measured as change from baseline. Before treatment, patients with MDD had 8% lower global 5-HT 4 R binding than controls (95%CI[-13.1%;-2.5%], p<0.001). Non-responders did not differ from controls, whereas remitters had 9% lower binding than controls ([-16.1%;-2.7%], p=0.004). Independent of treatment outcomes, patients reduced their neostriatal 5-HT 4 R binding (−9%, [-12.8%;-5.0%], p<0.001) after serotonergic intervention. Overall, patients with MDD have lower cerebral 5-HT 4 R binding than controls, suggesting that 5-HT 4 R is a biomarker for MDD. The observation that SSRI treatment leads to reduced neostriatal 5-HT 4 R binding supports that the treatment does indeed increase brain 5-HT levels. Patients who remit to SSRIs have lower cerebral 5-HT 4 R prior to treatment than controls whereas non-responders do not differ. We propose that non-responders to SSRI’s constitute a subgroup with non-serotonergic depression. ClinicalTrials.gov Identifier: NCT02869035 Registry name: Treatment Outcome in Major Depressive Disorder URL: https://clinicaltrials.gov/ct2/show/NCT02869035?term=NCT02869035&draw=2&rank=1
更多
查看译文
关键词
serotonergic subtype,major depressive disorder
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要